<DOC>
	<DOCNO>NCT01636531</DOCNO>
	<brief_summary>This multi-center , randomize , open-label , single-dose , parallel group study assess relative bioavailability , tolerability dose-exposure relationship high concentration liquid formulation ( HCLF ) versus lyophilize formulation ( LyoF ) gantenerumab ( RO4909832 ) healthy volunteer . Subjects randomize receive single subcutaneous dos either HCLF LyoF . Anticipated time treatment period follow-up 13 week .</brief_summary>
	<brief_title>A Study A High Concentration Liquid Formulation Versus A Lyophilized Formulation Gantenerumab Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy male female subject , 40 70 year age . Healthy status define absence evidence active chronic disease follow detailed medical surgical history complete physical examination Body mass index 18.0 30.0 kg/m2 inclusive Female subject either surgically sterilize postmenopausal Agree donate blood blood product transfusion duration study one year dose Suspicion alcohol drug abuse addiction Positive hepatitis B , hepatitis C HIV 1 2 infection Participation investigational drug device study within three month dose Concomitant disease condition treatment could interfere conduct study would , opinion investigator , pose unacceptable risk subject study Any clinically relevant history hypersensitivity allergic reaction , either spontaneous follow drug administration exposure food environmental agent Any familial history early onset Alzheimer 's disease Claustrophobia , presence pacemaker , aneurism clip , artificial heart valve , ear implant , foreign metal object eye , skin body would contraindicate MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>